Nurse Review of Research Councils

Nurse Review of Research Councils. The Nurse Review of Research Councils was an independent assessment of the United Kingdom's seven Research Councils, commissioned by the Chancellor of the Exchequer, George Osborne, and conducted by Nobel laureate Paul Nurse. Published in November 2015, the review examined the structure and effectiveness of the UK's public research funding system, aiming to enhance its contribution to national economic growth and scientific excellence. Its findings and recommendations directly informed the government's subsequent major reforms to the national research and innovation landscape.

Background and Context

The review was initiated against a backdrop of increasing global competition in science and innovation, with policymakers seeking to maximize the impact of public investment. The coalition government under David Cameron had previously conducted a Triennial Review of UK Research Councils in 2014, which identified areas for potential reform. Chancellor George Osborne, in his 2015 Budget statement, explicitly tasked Paul Nurse, then President of the Royal Society and director of the Francis Crick Institute, with leading a deeper examination. The core mandate was to assess whether the existing structure of Research Councils UK and its constituent bodies—including the Medical Research Council and the Engineering and Physical Sciences Research Council—remained fit for purpose in fostering world-class research and effective translation into economic benefits.

Key Recommendations

The review's central and most consequential proposal was the creation of a new overarching strategic body, tentatively named **Research UK (RUK)**. This entity would be governed by a single board with a strengthened chief executive, tasked with setting overarching strategy, allocating the science budget across councils, and championing interdisciplinary research. It recommended maintaining the seven individual councils as distinct entities to preserve their disciplinary expertise and community links. Other significant recommendations included establishing a common research fund to support cross-council initiatives, enhancing the role of Innovate UK within the ecosystem, and granting the new body greater autonomy from direct government department control to enable more agile, long-term decision-making.

Implementation and Impact

The government's response, detailed in the 2016 Higher Education and Research Bill, adopted the review's core architectural principle but implemented it through the creation of **UK Research and Innovation (UKRI)**. Established by the Higher Education and Research Act 2017, UK Research and Innovation subsumed the seven research councils, Innovate UK, and the research funding function of HEFCE into a single non-departmental public body. This major restructuring, which became operational in April 2018, was a direct translation of the Nurse Review's vision for a more coordinated and strategic national research endeavour. The formation of UK Research and Innovation represented the most significant reorganization of British science funding since the aftermath of the Rothschild report.

Reception and Criticism

The review was broadly welcomed by many in the scientific community, including the Royal Society and the Campaign for Science and Engineering, who praised its emphasis on strategic coordination and protecting the Haldane principle. However, it also faced significant criticism. Some, including the House of Commons Science and Technology Committee, expressed concerns that the proposed superstructure could add bureaucratic complexity and potentially undermine the autonomy of individual councils. Specific bodies like the Arts and Humanities Research Council worried their distinctive mission could be diluted within a larger, predominantly STEM-focused organization. Critics also argued the review did not adequately address chronic issues of underfunding or the stability of the Science budget of the United Kingdom.

Legacy and Subsequent Reviews

The Nurse Review is widely regarded as the foundational blueprint for the contemporary structure of British science funding. Its legacy is embodied in the enduring architecture of UK Research and Innovation, which continues to govern the distribution of billions in public research investment. Subsequent evaluations, such as the 2021 Independent Review of UK Research, Development and Innovation Organisations by Sir Paul Nurse and the 2023 Labour Party-commissioned review by Professor Sir John Kingman, have operated within the framework it established, often focusing on refining the model rather than proposing another wholesale restructuring. The review cemented Paul Nurse's influence as a key architect of modern UK science policy.